| Â | 2anti-V3 mAbs | Â |
|---|
1Protein/peptide | Subtype | I277 | I903 | I904 | A447-52D | 1418 |
|---|
Con-C V3
| C |
0.33
|
0.109
|
0.046
|
1.2
| >10 |
Con-B V3
| B | >10 | >10 |
0.623
|
0.323
| >10 |
Du156.12
| C |
0.047
|
0.019
|
0.009
|
0.035
| >10 |
JRFL
| B | >10 | >10 |
0.04
|
0.01
| >10 |
92RW020
| A |
0.098
|
0.05
|
0.028
|
0.323
| >10 |
SF162
| B | >10 | >10 | >10 |
0.004
| >10 |
MN
| B | >10 | >10 |
2.27
|
0.011
| >10 |
MPER
| C | >10 | >10 | >10 | >10 | >10 |
IDR
| C | >10 | >10 | >10 | >10 | >10 |
p24
| B | >10 | >10 | >10 | >10 | >10 |
BSA
| NA | >10 | >10 | >10 | >10 | >10 |
PP
| NA | >10 | >10 | >10 | >10 | >10 |
- 1List of recombinant proteins and peptides derived from subtype-A, B and C HIV-1 viruses, NA: Not applicable.
- 2Four anti-V3 antibodies, three from IndianI (277, 903 and 904) and one from AmericanA (447-52D) HIV-1 infected donor were tested for their relative binding. The binding activity of anti-V3 mAbs against proteins and peptides was tested by ELISA using mAbs at a concentration ranging from 10 to 0.00003 μg/ml (12 dilutions). The 50% binding titers (Max50, conc. μg/ml) of each antibody against the corresponding protein or peptide is depicted as numerical values in Bold (high affinity), Italic (low affinity) and >10, where Max50 value was not reached. Human anti-parvovirus B19 mAb 1418 was used as negative control. Each experiment was performed at least two independent times.
